The impact of MRTX1133 on anti-tumor immunity in lung cancer with KRASG12D mutation

被引：2
|
作者：
Shono, Kunihiro
Watanabe, Satoshi
Masuda, Takaaki
Suzuki, Ryo
Wakabayashi, Tomoya
Sekiya, Tomoki
Tanaka, Susumu
Ohtsubo, Aya
Tanaka, Tomohiro
Nozaki, Koichiro
Kondo, Rie
Saida, Yu
Hokari, Satoshi
Yanagimura, Naohiro
Arita, Masashi
Ohashi, Riuko
Shima, Kenjiro
Kimura, Yosuke
Aoki, Nobumasa
Ohshima, Yasuyoshi
Koya, Toshiyuki
Kikuchi, Toshiaki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5263
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The impact of MRTX1133 on anti-tumor immunity in lung cancer with KRASG12D mutation
    Shono, Kunihiro
    Watanabe, Satoshi
    Yamazaki, Ryo
    Ando, Yumi
    Masuda, Takaaki
    Suzuki, Ryo
    Wakabayashi, Tomoya
    Tanaka, Susumu
    Nozaki, Koichiro
    Saida, Yu
    Yanagimura, Naohiro
    Arita, Masashi
    Sato, Miyuki
    Ohashi, Riuko
    Kikuchi, Toshiaki
    CANCER SCIENCE, 2025, 116 : 508 - 508
  • [2] A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
    Wei, Daoyan
    Wang, Liang
    Zuo, Xiangsheng
    Maitra, Anirban
    Bresalier, Robert S.
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 655 - 662
  • [3] Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRASG12D Mutation
    Ji, Xiang
    Li, Yan
    Kong, Xianqi
    Chen, Dawei
    Lu, Jiasheng
    ACS OMEGA, 2023, : 7211 - 7221
  • [4] Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
    Wang, Xiaolun
    Allen, Shelley
    Blake, James F.
    Bowcut, Vickie
    Briere, David M.
    Calinisan, Andrew
    Dahlke, Joshua R.
    Fell, Jay B.
    Fischer, John P.
    Gunn, Robin J.
    Hallin, Jill
    Laguer, Jade
    Lawson, J. David
    Medwid, James
    Newhouse, Brad
    Phong Nguyen
    O'Leary, Jacob M.
    Olson, Peter
    Pajk, Spencer
    Rahbaek, Lisa
    Rodriguez, Mareli
    Smith, Christopher R.
    Tang, Tony P.
    Thomas, Nicole C.
    Vanderpool, Darin
    Vigers, Guy P.
    Christensen, James G.
    Marx, Matthew A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, : 3123 - 3133
  • [5] The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
    Christensen, James G.
    Hallin, Jill
    NATURE MEDICINE, 2022, 28 (10) : 2017 - 2018
  • [6] The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
    Nature Medicine, 2022, 28 : 2017 - 2018
  • [7] Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
    Abdul Rashid Issahaku
    Namutula Mukelabai
    Clement Agoni
    Mithun Rudrapal
    Sahar M. Aldosari
    Sami G. Almalki
    Johra Khan
    Scientific Reports, 12
  • [8] Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
    Issahaku, Abdul Rashid
    Mukelabai, Namutula
    Agoni, Clement
    Rudrapal, Mithun
    Aldosari, Sahar M.
    Almalki, Sami G.
    Khan, Johra
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [9] Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment
    Kataoka, Masahiro
    Kitazawa, Masato
    Nakamura, Satoshi
    Koyama, Makoto
    Yamamoto, Yuta
    Miyazaki, Satoru
    Hondo, Nao
    Tanaka, Hirokazu
    Soejima, Yuji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4341 - 4348
  • [10] Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
    Becker, Jeffrey H.
    Metropulos, Anastasia E.
    Spaulding, Christina
    Marinelarena, Alejandra M.
    Shields, Mario A.
    Principe, Daniel R.
    Pham, Thao D.
    Munshi, Hidayatullah G.
    CANCER RESEARCH, 2024, 84 (21) : 3629 - 3639
12345